Repository logo
 

Iron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

AbstractPersistent symptoms following SARS-CoV-2 infection are increasingly reported, although the drivers of post-acute sequelae (PASC) of COVID-19 are unclear. Here we assessed 214 individuals infected with SARS-CoV-2, with varying disease severity, for one year from COVID-19 symptom onset to determine the early correlates of PASC. A multivariate signature detected beyond two weeks of disease, encompassing unresolving inflammation, anemia, low serum iron, altered iron-homeostasis gene expression and emerging stress erythropoiesis; differentiated those who reported PASC months later, irrespective of COVID-19 severity. A whole-blood heme-metabolism signature, enriched in hospitalized patients at month 1–3 post onset, coincided with pronounced iron-deficient reticulocytosis. Lymphopenia and low numbers of dendritic cells persisted in those with PASC, and single-cell analysis reported iron maldistribution, suggesting monocyte iron loading and increased iron demand in proliferating lymphocytes. Thus, defects in iron homeostasis, dysregulated erythropoiesis and immune dysfunction due to COVID-19 possibly contribute to inefficient oxygen transport, inflammatory disequilibrium and persisting symptomatology, and may be therapeutically tractable.

Description

Acknowledgements: The members of the Cambridge Institute of Therapeutic Immunology and Infectious Disease–National Institute of Health Research (CITIID–NIHR COVID) BioResource are listed in the Supplementary Information and include the authors F.M., L.B., J.R.B., P.L. and K.G.C.S. We thank the NIHR BioResource volunteers for their participation, and acknowledge NIHR BioResource centers, NHS Trusts and staff for their contribution. We thank the National Institute for Health and Care Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR or Department of Health and Social Care. We acknowledge the services provided by the University of Cambridge Stratified Medicine Core Laboratory, NIHR Cambridge Biomedical Research Centre (BRC) Core Biochemistry Assay Laboratory, NIHR Cambridge BRC Cell Phenotyping Hub, Cambridge Clinical Immunology Laboratory and University of Cambridge Department of Haematology for sample processing and biological data generation. We thank J. Stevens and L. Stefanucci from the Department of Haematology, University of Cambridge for their involvement in hematology data collection, and M. Potts and M. Weekes from the Department of Medicine, University of Cambridge for providing mass spectrometry data. We thank J. Frost from the Weatherall Institute of Molecular Medicine, University of Oxford MRC for his valuable contribution to the scientific interpretation of findings and manuscript structuring. We thank CVC Capital Partners, the Evelyn Trust (20/75), Addenbrooke’s Charitable Trust, Cambridge University Hospitals (12/20A), the NIHR Cambridge Biomedical Research Centre and the UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) for their financial support. The BioResource was funded by awards from NIHR to the NIHR BioResource (grant numbers RG94028 and RG85445). K.G.C.S. was funded by a Wellcome Investigator Award (grant number 200871/Z/16/Z) and MRC Programme Grant (grant number MR/W018861/1). A.L.H. was funded by the EU H2020 project SYSCID Grant (grant number 733100).

Keywords

Journal Title

Nature Immunology

Conference Name

Journal ISSN

1529-2908
1529-2916

Volume Title

25

Publisher

Springer Science and Business Media LLC

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Wellcome Trust (Wellcome) (200871/Z/16/Z)
RCUK | MRC | Medical Research Foundation (MR/W018861/1)
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) (733100)